Invention Grant
- Patent Title: Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
-
Application No.: US17000271Application Date: 2020-08-21
-
Publication No.: US11364241B2Publication Date: 2022-06-21
- Inventor: Bing Wang , Daniel Chu
- Applicant: Medivation Technologies LLC
- Applicant Address: US NY New York
- Assignee: Medivation Technologies LLC
- Current Assignee: Medivation Technologies LLC
- Current Assignee Address: US NY New York
- Agency: Pfizer Inc.
- Main IPC: A61K31/5025
- IPC: A61K31/5025 ; A61K33/243 ; C07D471/06 ; A61K31/5377 ; A61K31/282 ; A61K31/4745 ; A61K31/495 ; A61N5/10

Abstract:
A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.
Public/Granted literature
- US20210069191A1 DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) Public/Granted day:2021-03-11
Information query
IPC分类: